With this fresh capital, the Bengaluru-based company aims to accelerate its AI-driven product development and expand its global market presence.

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

The ASX retreated from earlier gains and closed 0.25% lower on Tuesday, following a late-day tumble in pharma giant CSL ...

ASX rises with Nvidia and gold's record high, Trump’s tariffs hit, Albanese talks to Trump, Musk’s OpenAI bid blocked.

Chesley "Sully" Sullenberger, known for the heroic landing of US Airways Flight 1549 on the Hudson River, weighed in on the ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Sana Biotechnology and Vertex Pharmaceuticals represent the region’s leadership in cell and gene therapy, while Inventprise reflects Washington’s roots in global health and vaccines.

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...